نتایج جستجو برای: jak2 v617f

تعداد نتایج: 4704  

Journal: :Haematologica 2009
Valerio De Stefano Tommaso Za Elena Rossi Alessia Fiorini Angela Ciminello Claudia Luzzi Patrizia Chiusolo Simona Sica Giuseppe Leone

It is uncertain whether the JAK2 V617F mutation increases the thrombotic risk in patients with essential thrombocythemia, and it is unknown whether inherited thrombophilia is an additive risk factor in mutated subjects. We studied 132 patients with essential thrombocythemia, 38 of them (29%) with a history of thrombosis. The JAK2 mutation was present in 83 (63%), and inherited thrombophilia in ...

2011
Tamotsu Irino Munehiro Uemura Humitsugu Yamane Shigeto Umemura Takahiko Utsumi Naoki Kakazu Taku Shirakawa Mitsuhiro Ito Takayo Suzuki Kazuo Kinoshita

Myeloproliferative neoplasms (MPN) are multiple disease entities characterized by clonal expansion of one or more of the myeloid lineages (i.e. granulocytic, erythroid, megakaryocytic and mast cell). JAK2 mutations, such as the common V617F substitution and the less common exon 12 mutations, are frequently detected in such tumor cells and have been incorporated into the diagnostic criteria publ...

2016
A. ILEA A. M. VLADAREANU E. NICULESCU-MIZIL

Although the discovery of the BCR-ABL transcript and of the Jak2 V617F mutation lead to important clarifications, the pathogenesis of chronic myeloproliferative neoplasms remains extremely complex and still presents several unknowns. Our study reports the case of a 52 years old man with chronic myeloid leukemia (BCR-ABL positive) who, after 4 years of targeted therapy with tyrosine kinase inhib...

2015
Stephen E. Langabeer James Nolan Karl Haslam Lindsey Clarke Richard Flavin Eibhlin Conneally

Monitoring of the JAK2 V617F allele burden in myeloproliferative neoplasms after allogeneic stem cell transplantation is useful to determine levels of residual disease and has the potential to detect early relapse and guide subsequent clinical intervention. A case is described of a JAK2 V617F-positive primary myelofibrosis patient who underwent allogeneic stem cell transplantation. Prospective ...

2011
Zhiyuan Wu Hong Yuan Xinju Zhang Weiwei Liu Jinhua Xu Wei Zhang Ming Guan

BACKGROUND JAK2 V617F, a somatic point mutation that leads to constitutive JAK2 phosphorylation and kinase activation, has been incorporated into the WHO classification and diagnostic criteria of myeloid neoplasms. Although various approaches such as restriction fragment length polymorphism, amplification refractory mutation system and real-time PCR have been developed for its detection, a gene...

Journal: :Blood 2014
Caroline Marty Cécile Saint-Martin Christian Pecquet Sarah Grosjean Joseph Saliba Céline Mouton Emilie Leroy Ashot S Harutyunyan Jean-François Abgrall Rémi Favier Aurélie Toussaint Eric Solary Robert Kralovics Stefan N Constantinescu Albert Najman William Vainchenker Isabelle Plo Christine Bellanné-Chantelot

The main molecular basis of essential thrombocythemia and hereditary thrombocytosis is acquired, and germ-line-activating mutations affect the thrombopoietin signaling axis. We have identified 2 families with hereditary thrombocytosis presenting novel heterozygous germ-line mutations of JAK2. One family carries the JAK2 R867Q mutation located in the kinase domain, whereas the other presents 2 J...

Journal: :Blood 2006
Jean-Jacques Kiladjian Bruno Cassinat Pascal Turlure Nathalie Cambier Murielle Roussel Sylvia Bellucci Marie-Laurence Menot Gerald Massonnet Jean-Luc Dutel Kamel Ghomari Philippe Rousselot Marie-Jose Grange Yasmina Chait William Vainchenker Nathalie Parquet Lina Abdelkader-Aljassem Jean-François Bernard Jean-Didier Rain Sylvie Chevret Christine Chomienne Pierre Fenaux

V617F JAK2 mutation is a reliable molecular marker of polycythemia vera (PV), potentially useful to monitor the effect of treatments in this disease. In a phase 2 study of pegylated (peg) IFN-alpha-2a in PV, we performed prospective sequential quantitative evaluation of the percentage of mutated JAK2 allele (%V617F) by real-time polymerase chain reaction (PCR). The %V617F decreased in 24 (89%) ...

2011
Luca Zito Roberto Torchio Kassem Bannout Stefano Ulisciani Marco Guglielmo Claudio Ciacco Donatella Lodico

SUMMARY This case report focuses on a 71-year old patient affected by unknown dyspnea and erythrocytosis referred by his general practitioner to our center for specialist advice after a hematological examination had excluded polycythemia vera on grounds of negative test for JAK2 V617F/exon 12 mutation. An accurate clinical history and physical examination accompanied by respiratory function tes...

Journal: :Haematologica 2007
Luz Martínez-Avilés Carles Besses Alberto Alvarez-Larrán Francisco Cervantes Juan Carlos Hernández-Boluda Beatriz Bellosillo

JAK2 exon 12 mutations were detected in 4 out of 20 polycythemia vera and idiopathic erythrocytosis V617F-negative patients and were only present in the myeloid lineage. Initial hematologic data of these patients differ from those of V617F-positive patients, but there is no difference in thrombotic development and myelofibrotic transformation.

2014
Adrian P. Trifa Andrei Cucuianu Radu A. Popp

Familial essential thrombocythemia features the acquisition of somatic mutations and an evolution similar to the sporadic form of the disease. Here we report two patients-father and daughter-with essential thrombocythemia who displayed a heterogeneous pattern of somatic mutations. The JAK2 V617F mutation was found in the daughter, while the father harbored the MPL W515L mutation. This case repo...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید